Ahead of the forthcoming Summer Meeting of the British Association for Psychopharmacology [BAP], Professor Catherine Harmer of Oxford University*, said: “I do think the BAP has a really important role in being a source of good quality information”.
This reminds me that Professor Stephen Stahl described a previous BAP Summer Meeting as a “robust learning environment for UK health professionals” but failed to disclose that in the previous two years he had been paid $3.5 million dollars by the pharmaceutical industry.
Evidence of the last decade of Summer Meetings confirms that BAP actually provides a robust marketplace for the pharmaceutical industry. The Royal College of Psychiatrists has continued to support this conflation of marketing with education: year after year after year.
Please click on the above image for evidence of the immersion of the pharmaceutical industry in providing BAP education.
* Professor Harmer will become President of BAP at this years Summer Meeting.